Analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to announce ($0.91) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Neurocrine Biosciences’ earnings. The highest EPS estimate is $0.09 and the lowest is ($1.40). Neurocrine Biosciences posted earnings of ($0.47) per share in the same quarter last year, which suggests a negative year over year growth rate of 93.6%. The firm is expected to issue its next earnings report on Monday, April 29th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of $0.13 per share for the current year, with EPS estimates ranging from ($1.01) to $2.11. For the next financial year, analysts expect that the company will report earnings of $3.11 per share, with EPS estimates ranging from $2.25 to $3.92. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Tuesday, February 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.05. Neurocrine Biosciences had a net margin of 4.68% and a return on equity of 5.06%. The firm had revenue of $131.49 million during the quarter, compared to analysts’ expectations of $132.32 million. During the same quarter in the prior year, the business earned $0.07 earnings per share. The business’s revenue for the quarter was up 39.1% compared to the same quarter last year.
In other news, insider Kyle Gano sold 3,809 shares of the business’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $88.12, for a total transaction of $335,649.08. Following the transaction, the insider now directly owns 17,595 shares of the company’s stock, valued at $1,550,471.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin Charles Gorman sold 7,614 shares of the business’s stock in a transaction that occurred on Tuesday, February 5th. The shares were sold at an average price of $88.16, for a total value of $671,250.24. Following the transaction, the chief executive officer now directly owns 408,082 shares in the company, valued at $35,976,509.12. The disclosure for this sale can be found here. Insiders sold a total of 13,280 shares of company stock valued at $1,163,054 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Eaton Vance Management lifted its holdings in shares of Neurocrine Biosciences by 20.8% during the fourth quarter. Eaton Vance Management now owns 129,434 shares of the company’s stock valued at $9,243,000 after purchasing an additional 22,280 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in Neurocrine Biosciences by 106.6% in the third quarter. Advisors Asset Management Inc. now owns 7,030 shares of the company’s stock valued at $864,000 after acquiring an additional 3,628 shares during the period. Standard Life Aberdeen plc bought a new position in Neurocrine Biosciences in the third quarter valued at about $16,815,000. Pacer Advisors Inc. bought a new position in Neurocrine Biosciences in the third quarter valued at about $327,000. Finally, NumerixS Investment Technologies Inc lifted its holdings in Neurocrine Biosciences by 75.2% in the fourth quarter. NumerixS Investment Technologies Inc now owns 3,300 shares of the company’s stock valued at $226,000 after acquiring an additional 1,416 shares during the period.
Shares of NBIX traded up $1.04 during trading hours on Wednesday, reaching $91.03. The stock had a trading volume of 67,317 shares, compared to its average volume of 727,902. Neurocrine Biosciences has a 12 month low of $64.72 and a 12 month high of $126.98. The company has a quick ratio of 8.24, a current ratio of 8.36 and a debt-to-equity ratio of 0.81. The stock has a market cap of $8.24 billion, a P/E ratio of 414.18, a P/E/G ratio of 28.60 and a beta of 1.87.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Recommended Story: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.